<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-66" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Fenofibrate</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sidhu</surname>
            <given-names>Gursharan</given-names>
          </name>
          <aff>Avalon University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tripp</surname>
            <given-names>Jayson</given-names>
          </name>
          <aff>CUSOM/Cape Fear Valley Health Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gursharan Sidhu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jayson Tripp declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>13</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-66.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Fenofibrate is FDA approved to treat patients with hypertriglyceridemia, primary hypercholesterolemia, or mixed dyslipidemia. It reduces low-density lipoprotein cholesterol (LDL-C), total cholesterol, triglycerides, and apolipoprotein B and increases high-density lipoprotein cholesterol (HDL-C) in adults. Fenofibrate should be used in conjunction with a restriction of cholesterol and fat intake and exercise if the response to diet and nonpharmacological interventions alone has been inadequate. Secondary causes of hyperlipidemia should be ruled out before initiating therapy. The therapy should be administered for at least 2 to 3 months before assessing for efficacy. This activity covers the indications, dosing, contraindications, monitoring, and toxicity of fenofibrate so the interprofessional team can optimize its use in therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of fenofibrate.</p></list-item><list-item><p>Describe the potential adverse effects of fenofibrate.</p></list-item><list-item><p>Review the appropriate monitoring of fenofibrate.</p></list-item><list-item><p>Discuss interprofessional team strategies for improving care coordination and communication to advance fenofibrate and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=66&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=66">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-66.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Fenofibrate is FDA approved for the management and treatment of hypertriglyceridemia, primary hypercholesterolemia, or mixed dyslipidemia. It reduces low-density lipoprotein, triglycerides, and total cholesterol while increasing high-density lipoprotein cholesterol in adults. Fenofibrate should be used in conjunction with a restriction of cholesterol intake and exercise if lifestyle modifications alone have been insufficient.<xref ref-type="bibr" rid="article-66.r1">[1]</xref>&#x000a0;Before initiating treatment, the clinician needs to rule out hyperlipidemia or dyslipidemia due to secondary causes.&#x000a0;The medication is safe and effective for use in the geriatric population. However, drug safety and efficacy are unestablished in the pediatrics population. Fenobrifate may be used in pregnancy if the potential benefits outweigh the potential risk to the fetus. Off-label fenofibrate may be used as adjunctive therapy for elevated blood uric acid levels in individuals with gout.<xref ref-type="bibr" rid="article-66.r2">[2]</xref></p>
      </sec>
      <sec id="article-66.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Fibrates such as fenofibrate activate peroxisome proliferator-activated receptors alpha (PPAR-alpha), which upregulate lipoprotein lipase, induce high-density lipoprotein (HDL) synthesis, and decrease liver production of apolipoprotein C. Fibrates ultimately enhance the clearance of triglyceride-rich particles and plasma catabolism. Fibrates also enhance fatty acid oxidation via acyl CoA synthetase and other enzymes, further reducing triglycerides' synthesis. The end result is an overall reduction of plasma triglyceride and very-low-density lipoprotein (VLDL) levels. The decrease in VLDL can cause plasma triglyceride levels to decrease by 30%&#x000a0;to 60%. In addition, fenofibrate may facilitate an increase in uric acid excretion and reduction of fibrinogen, which may help patients with gout and thrombosis.<xref ref-type="bibr" rid="article-66.r3">[3]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Fenofibrate is&#x000a0;well-absorbed (approximately 60%) after oral administration with a time of peak plasma concentration reaching 4 to&#x000a0;8 hours.&#x000a0;It is a highly protein-bound drug (99%), and its steady-state concentration is reached within five days of administration.&#x000a0;It is hydrolyzed into a primary metabolite, fenofibric acid, which is further&#x000a0;conjugated with glucuronic acid. Fenofibrate has a terminal half-life of 20 to 23 hours. About 60% of the dose is excreted in the urine, and about 25% is excreted&#x000a0;in the feces.<xref ref-type="bibr" rid="article-66.r4">[4]</xref></p>
      </sec>
      <sec id="article-66.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Fenofibrate capsules and tablets are administered orally once daily with or without food. The capsules should be swallowed whole and should not be crushed, dissolved, or chewed. Fenofibrate therapy may be considered an option for individuals taking moderate-intensity statin therapy if the benefits&#x000a0;(i.e., decreasing cardiovascular disease risk) outweigh the potential risks of adverse effects. Dose adjustments are made at 4&#x000a0;to 8-week intervals based on the individual patient response.<xref ref-type="bibr" rid="article-66.r3">[3]</xref></p>
        <p>It is available in the following oral dosage formulations, and formulation change should be done carefully as formulations are not bio-equivalent:</p>
        <p>Capsule of fenofibrate: 30 mg, 43 mg, 50 mg, 67 mg, 90 mg, 130 mg, 134 mg, 150 mg, and 200 mg</p>
        <p>Delayed-Release capsule of choline fenofibrate: 45 mg and 135 mg</p>
        <p>Tablet of feno-fibric acid: 35 mg and 105 mg</p>
        <p>Tablet of fenofibrate: 40 mg, 48 mg, 54 mg, 120 mg, 145 mg, and 160 mg</p>
        <p><bold>Adult Dosing&#x000a0;&#x000a0;</bold>(dose of tablets of fenofibrate)</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertriglyceridemia (type IV or V)
<list list-type="bullet"><list-item><p>54 to 160 mg daily&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Primary Hypercholesterolemia
<list list-type="bullet"><list-item><p>160 mg daily&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Mixed dyslipidemia
<list list-type="bullet"><list-item><p>160 mg daily&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>Specific Patient Population&#x000a0;</bold></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Patient with Hepatic Impairment:&#x000a0;</bold>There is no dose adjustment guidance in the manufacturer label for patients with hepatic impairment. However, the drug should be used with caution in these patients. Liver function monitoring is recommended.<xref ref-type="bibr" rid="article-66.r4">[4]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Patient with Renal Impairment:&#x000a0; </bold>No dose adjustment is necessary for patients with renal impairment if creatinine clearance is above 80 mL/min. For moderate impairment, start the patient at 40 to 54 mg daily. Fenofibrate is contraindicated if creatinine clearance is under 30 mL/min or if the patient has severe renal dysfunction.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pregnancy Implications:&#x000a0;</bold>It is considered as pregnancy category C medicine. However, due to limited data on fenofibrate use in pregnant women, it is not sufficient to determine the risk of major congenital disabilities, adverse maternal or fetal outcomes, or&#x000a0;miscarriage-related risk associated with this drug.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Breastfeeding Implications:</bold>&#x000a0;There is no information available on the presence of&#x000a0;this drug in human milk. The effects of the drug on milk production or the breastfed infant are also unknown.<xref ref-type="bibr" rid="article-66.r5">[5]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pediatric Patients:&#x000a0;</bold>The safety and efficacy are not established in pediatric patients.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Geriatric Patients:&#x000a0;</bold>Based on the safety and efficacy studies in elderly volunteers 77 &#x02013; 87 years of age, the oral clearance of the drug in geriatric patients is similar to that of adults, so there is no dose adjustment or specific dosage regimen&#x000a0;needed for geriatric patients. It is recommended to start the dose based on renal function and product-specific labeling.<xref ref-type="bibr" rid="article-66.r3">[3]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-66.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Some of the most common adverse effects of fibrates include headaches, dizziness, back pain, joint pain, asthenia, diarrhea, nausea, constipation, dyspepsia, cough, wheezing, nasopharyngitis, and flu-like symptoms. Some potentially serious adverse effects that may require dose adjustment or discontinuation may include elevated liver enzymes, elevated creatine phosphokinase (CPK), cholelithiasis development, arrhythmia exacerbation, pulmonary embolism, pancreatitis, agranulocytosis, and myocardial infarction.<xref ref-type="bibr" rid="article-66.r6">[6]</xref></p>
        <p>
<bold>Drug Interactions</bold>
</p>
        <p>Bile acid sequestrants: It is recommended to modify therapy when bile acid sequestrants are coadministered with fenofibrate as they may decrease the overall absorption of the fibric acid. If coadministration of these drugs is necessary, it is recommended to administer the fenofibrate one hour prior or&#x000a0;four to six&#x000a0;hours after a bile acid sequestrant.&#x000a0;</p>
        <p>Ciprofibrate:&#x000a0;As both ciprofibrate and fenofibrate are fabric acid derivatives, the coadministration of these medicines may enhance the adverse toxic effect associated with fibric acid derivatives. It is highly recommended to avoid this combination.</p>
        <p>Systemic cyclosporine:&#x000a0;It is recommended to modify therapy when&#x000a0;fenofibrate is&#x000a0;coadministered with systemic cyclosporine. This combination may lead to the increased nephrotoxic effect of fibric acid. Therefore, it is recommended to either modify therapy or monitor renal function closely if these drugs are coadministered.<xref ref-type="bibr" rid="article-66.r7">[7]</xref></p>
        <p>Warfarin or vitamin K antagonists:&#x000a0;It is recommended to modify therapy when&#x000a0;fenofibrate is&#x000a0;coadministered with warfarin or&#x000a0;vitamin K&#x000a0;antagonists as fenofibrate may enhance the anticoagulant effect of warfarin or&#x000a0;vitamin K&#x000a0;antagonists.<xref ref-type="bibr" rid="article-66.r8">[8]</xref></p>
      </sec>
      <sec id="article-66.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Fenofibrate is contraindicated for patients with a history of hypersensitivity to fenofibrate, liver disease, severe renal dysfunction, preexisting gallbladder disease, or breastfeeding. Fenofibrate may also interact with other drugs and may require a change in dose, frequency, or switching to a new therapy. When prescribing fenofibrate in conjunction with statins (HMG-CoA reductase inhibitors) or colchicine, rhabdomyolysis and myopathy may occur. There is also an increased incidence of myopathy related to fenofibrate therapy in patients diagnosed with diabetes mellitus, thyroid disorder, or a renal disorder.<xref ref-type="bibr" rid="article-66.r3">[3]</xref></p>
        <p>Fibrates, especially gemfibrozil, are associated with an increased risk of cholecystitis and cholelithiasis due to their ability to increase the cholesterol saturation in bile. Patients with severe renal dysfunction, including those on dialysis, should avoid fenofibrate due to reduced drug clearance and increased risk of myositis. Caution is necessary if patients are on anticoagulation therapy as fenofibrate may potentiate the effects of coumarin-type medications.<xref ref-type="bibr" rid="article-66.r9">[9]</xref></p>
      </sec>
      <sec id="article-66.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients on fenofibrate should undergo monitoring for the effectiveness of treating a medical condition and any adverse effects pertaining to the medication. A complete list of patient medications should be reviewed before initiating drug therapy. The clinician should discontinue treatment if an inadequate response is not seen within two to three months of beginning the fenofibrate therapy. Kidney function labs such as uric acid (UA), blood urea nitrogen (BUN), and creatine clearance (CrCl) should have regular monitoring in individuals with renal impairment, and dosing should be adjusted as needed. The hepatic function is crucial to monitor to avoid administering the medication to individuals with an active hepatic disorder or persistently elevated serum transaminases.<xref ref-type="bibr" rid="article-66.r10">[10]</xref> Regular monitoring of creatine phosphokinase (CPK) levels is required to check for any signs and symptoms of myopathy or rhabdomyolysis. Blood counts should also be periodically monitored to reduce risks of thrombocytopenia and agranulocytosis. A periodic lipid panel, including total cholesterol, HDL, LDL, and triglyceride levels, should be conducted to assess drug safety and efficacy.&#x000a0;Fenofibrate should be stored in a cool place away from light and moisture.<xref ref-type="bibr" rid="article-66.r11">[11]</xref></p>
      </sec>
      <sec id="article-66.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The most common toxicity associated with fenofibrate is myopathy when given with statin medicines concurrently. If rhabdomyolysis is excluded and other muscle-related diseases are suspected, the statin-associated muscle symptoms clinical index (SAMS-CI) should be evaluated to determine if muscle symptoms are due to statin therapy. Discontinuing fenofibrate, administering vitamin D replacement (for low vitamin D levels), and switching the medication are all possible options depending on the cause of&#x000a0;myopathy.<xref ref-type="bibr" rid="article-66.r12">[12]</xref></p>
        <p>There is no specific treatment available for&#x000a0;the overdose of fenofibrate. General supportive care is recommended&#x000a0;for the patient. The vital signs and clinical status should be monitored if an overdose occurs. If&#x000a0;needed, the elimination of unabsorbed drugs should be attained by emesis or gastric lavage. Monitoring of clear airway is also recommended. As fenofibric acid&#x000a0;has high&#x000a0;plasma proteins binding, hemodialysis for eliminating drugs should not be considered.</p>
      </sec>
      <sec id="article-66.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interprofessional healthcare team&#x000a0;including clinicians, mid-level practitioners (NPs and PAs), nurses, and pharmacists is optimal for managing treatment with fenofibrate. Medical professionals should be aware of the signs and symptoms accompanying fenofibrate toxicity. The involvement of other specialized professionals, including a nephrologist or toxicologist, should be considered to ensure an optimal patient result. Clinicians must counsel patients regarding any symptoms associated with liver damage (weakness, weight change, abdominal pain, jaundice). Interprofessional care coordination with open communication among team members will result in the best possible outcomes with the fewest adverse events. [Level 5]</p>
        <p>Pharmacists should actively monitor drug interactions before dispensing medication and notify the&#x000a0;prescriber or nurse of potential issues. In addition, the medical care provider should advise the patient on the importance of reading labels pertaining to the medication to avoid drug misuse or overdose. An interactive team dynamic for fenofibrate therapy is essential in managing any adverse effects and providing successful patient care for an optimal therapeutic outcome.</p>
      </sec>
      <sec id="article-66.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=66&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=66">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/66/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=66">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-66.s11">
        <title>References</title>
        <ref id="article-66.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kay&#x00131;k&#x000e7;&#x00131;o&#x0011f;lu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shahbazova</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>&#x00130;brahimov</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Can</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort.</article-title>
            <source>Turk Kardiyol Dern Ars</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>48</volume>
            <issue>4</issue>
            <fpage>359</fpage>
            <page-range>359-367</page-range>
            <pub-id pub-id-type="pmid">32519982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jung</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Effect of fenofibrate on uric acid level in patients with gout.</article-title>
            <source>Sci Rep</source>
            <year>2018</year>
            <month>Nov</month>
            <day>13</day>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>16767</fpage>
            <pub-id pub-id-type="pmid">30425304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKeage</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Fenofibrate: a review of its use in dyslipidaemia.</article-title>
            <source>Drugs</source>
            <year>2011</year>
            <month>Oct</month>
            <day>01</day>
            <volume>71</volume>
            <issue>14</issue>
            <fpage>1917</fpage>
            <page-range>1917-46</page-range>
            <pub-id pub-id-type="pmid">21942979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balfour</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>McTavish</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Heel</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.</article-title>
            <source>Drugs</source>
            <year>1990</year>
            <month>Aug</month>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>260</fpage>
            <page-range>260-90</page-range>
            <pub-id pub-id-type="pmid">2226216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <chapter-title>Fenofibrate</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>6</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">30000697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>YQ</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of coenzyme A versus fenofibrate in patients with hyperlipidemia: a multicenter, double-blind, double-mimic, randomized clinical trial.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>941</fpage>
            <page-range>941-945</page-range>
            <pub-id pub-id-type="pmid">32212983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lozada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dujovne</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Drug interactions with fibric acids.</article-title>
            <source>Pharmacol Ther</source>
            <year>1994</year>
            <month>Aug</month>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>163</fpage>
            <page-range>163-76</page-range>
            <pub-id pub-id-type="pmid">7809177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leonard</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Brensinger</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Bilker</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Kimmel</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Nam</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Gagne</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Mangaali</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hennessy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics.</article-title>
            <source>Int J Cardiol</source>
            <year>2017</year>
            <month>Feb</month>
            <day>01</day>
            <volume>228</volume>
            <fpage>761</fpage>
            <page-range>761-770</page-range>
            <pub-id pub-id-type="pmid">27888753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <article-title>[Part III. Clinical control of fenofibrate therapy].</article-title>
            <source>Clin Investig Arterioscler</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>28 Suppl 3</volume>
            <fpage>20</fpage>
            <page-range>20-5</page-range>
            <pub-id pub-id-type="pmid">27473467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hedrington</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>Peroxisome proliferator-activated receptor alpha-mediated drug toxicity in the liver.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>14</volume>
            <issue>7</issue>
            <fpage>671</fpage>
            <page-range>671-677</page-range>
            <pub-id pub-id-type="pmid">29847748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chachad</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Gole</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Malhotra</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Naidu</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Comparison of pharmacokinetics of two fenofibrate tablet formulations in healthy human subjects.</article-title>
            <source>Clin Ther</source>
            <year>2014</year>
            <month>Jun</month>
            <day>01</day>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>967</fpage>
            <page-range>967-73</page-range>
            <pub-id pub-id-type="pmid">24844853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-66.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kawata</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yokoi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Analysis of a Skeletal Muscle Injury and Drug Interactions in Lovastatin- and Fenofibrate-Coadministered Dogs.</article-title>
            <source>Int J Toxicol</source>
            <year>2019</year>
            <season>May/Jun</season>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>192</fpage>
            <page-range>192-201</page-range>
            <pub-id pub-id-type="pmid">31113311</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
